MD1003 (High-Dose Pharmaceutical Biotin) for the Treatment of Progressive Multiple Sclerosis: Baseline Data and Results from an Early Access Program

被引：0

作者：

Brassat, David ^{[1
]}

Hautecoeur, Patrick ^{[2
]}

Durand-Dubief, Francoise ^{[3
]}

Castelnovo, Giovanni ^{[4
]}

Derache, Nathalie ^{[5
]}

Bourre, Bertrand ^{[6
]}

Donze, Cecile ^{[2
]}

Ouallet, Jean-Christophe ^{[7
]}

Collongues, Nicolas ^{[8
]}

Simon, Olivier ^{[9
]}

Brion, Guillaume ^{[9
]}

Sedel, Frederic ^{[9
]}

Vermersch, Patrick ^{[10
]}

Lasser, Robert ^{[9
]}

Morteau, Olivier ^{[9
]}

机构：

[1] Univ Hosp Toulouse, Toulouse, France

[2] Catholic Inst Lille, Groupement Hop, Lomme Les Lille, France

[3] Pierre Wertheimer Hosp, Rhone, France

[4] Caremeau Hosp, Rhone, France

[5] CHU Caen, Caen, France

[6] Rouen Normandy Univ, Rouen, France

[7] Univ Bordeaux, Bordeaux, France

[8] Univ Hosp Strasbourg, Strasbourg, France

[9] MedDay Pharmaceut, Paris, France

[10] Univ Lille, Lille, France

来源：

MULTIPLE SCLEROSIS JOURNAL | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P046

引用

页码：31 / 32

页数：2

共 50 条

[21] Real-world effectiveness of MD1003 (high dose pharmaceutical grade biotin) in patients with progressive MS
Faure, J.
Jauffret, J.
Carreau, C.
Legrain, P.
Castex, C.
Tourbah, A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 281 - 282
[22] MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial
Tourbah, A.
Lebrun-Frenay, C.
Edan, G.
Clanet, M.
Papex, C.
Vukusic, S.
De Sesze, J.
Debouverie, M.
Gout, O.
Clavelou, P.
Defer, G.
Laplaud, D.
Moreau, T.
Labauge, P.
Brochet, B.
Sedel, F.
Pelletier, J.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 785 - 785
[23] NFL pattern in progressive Multiple Sclerosis cohort under MD1003 treatment
Pignolet, Beatrice
Ammoscato, Francesca
Ciron, Jonathan
Bucciarelli, Florence
Scandella, Lise
Biotti, Damien
Lerebours, Fleur
Dorcet, Guillaume
Rabadeux, Celine
Freitas, Noellie
Bonneville, Fabrice
Gnanapavan, Sharmilee
Brassat, David
[J]. NEUROLOGY, 2019, 92 (15)
[24] Efficacy and safety results of the phase 3 SPI2 study of MD1003 (high dose Pharmaceutical grade Biotin) in progressive MS
Cree, B. A. C.
Cutter, G.
Wolinsky, J. S.
Freedman, M. S.
Comi, G.
Giovannoni, G.
Hartung, H. -P.
Sedel, F.
Lublin, F.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 46 - 46
[25] Effect of MD1003 (high dose pharmaceutical grade biotin) on dexterity, cognitive, and quality of life measures in a cohort of patients with non-active progressive multiple sclerosis
Donze, C.
Guyot, M. A.
Lenne, B.
Massot, C.
Kwiatkowski, A.
Hautecoeur, P.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 915 - 915
[26] Immunomodulation associated with clinical and MRI worsening in patients with progressive MS treated with MD1003 (high dose pharmaceutical grade biotin)
Pignolet, B.
Ciron, J.
Bucciarelli, F.
Scandella, L.
Biotti, D.
Lerebours, F.
Dorcet, G.
Rabadeux, C.
Freitas, N.
Bonneville, F.
Brassat, D.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 467 - 468
[27] Effect of MD1003 (high dose pharmaceutical grade biotin) for the treatment of progressive MS: long-term safety data at 60 months of follow-up
de Seze, J.
Edan, G.
Moreau, T.
Sedel, F.
Tourbah, A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 773 - 774
[28] Beneficial Effects of High-dose Biotin (MD1003) in Models of X-linked adrenoleukodystrophy
Fourcade, Stephane
Parameswaran, Janani
Goicoechea, Leire
Launay, Nathalie
Ruiz, Montserrat
Sedel, Frederic
Pujol, Aurora
[J]. NEUROLOGY, 2019, 92 (15)
[29] Beneficial effects of high-dose biotin (MD1003) in models of X-linked adrenoleukodystrophy
Fourcade, S.
Parameswaran, J.
Goicoechea, L.
Launay, N.
Ruiz, M.
Sedel, F.
Pujol, A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 521 - 522
[30] Effect of MD1003 (high dose pharmaceutical grade Biotin) for the treatment of progressive MS: long-term safety data at 48 months of follow-up
De Seze, J.
Edan, G.
Moreau, T.
Sedel, F.
Tourbah, A.
Krijnen, E.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 860 - 860

← 1 2 3 4 5 →